Editas Medicine, Inc.
EDIT· Nasdaq
EDITEditas Medicine, Inc.
Filed Feb 22, 2023 · 10-K · 53 days after period end · 0001558370-23-001764
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $6.54M | $12.47M | $11.42M | $12.28M |
| Net Income | -$60.74M | -$41.44M | -$62.50M | -$37.77M |
| EPS Diluted | — | — | -$1.00 | — |
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 22, 2023 · 53 d after period end
